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Abstract
Purpose Pain, fatigue and depression are common sequelae of a cancer diagnosis. The extent to which these occur together in
prostate cancer survivors is unknown. We (i) investigated prevalence of the pain-fatigue-depression symptom cluster and (ii)
identified factors associated with experiencing the symptom cluster among prostate cancer survivors.
Methods Men in Ireland diagnosed with prostate cancer 2–18 years previously were identified from population-based cancer
registries and sent postal questionnaires. Cancer-related pain and fatigue were measured using the EORTC QLQ-C30 and
depression using the DASS-21. Cut-offs to define ‘caseness’ were pain ≥ 25, fatigue ≥ 39 and depression ≥ 10. Associations
between survivor-related factors, clinical variables and specific prostate cancer physical symptoms and the symptom cluster were
assessed using multivariate logistic regression.
Results A total of 3348 men participated (response rate = 54%). Twenty-four percent had clinically significant pain, 19.7% had
clinically significant fatigue, and 14.4% had depression; 7.3% had all three symptoms. In multivariate analysis, factors signif-
icantly associated with the symptom cluster were living in Northern Ireland, experiencing back pain at diagnosis and being
affected by incontinence, loss of sexual desire, bowel problems, gynecomastia and hot flashes post-treatment. There was a strong
association between the cluster and health-related quality of life.
Conclusions The pain-fatigue-depression symptom cluster is present in 1 in 13 prostate cancer survivors. Physical after-effects of
prostate cancer treatment are associated with this cluster. More attention should be paid to identifying and supporting survivors
who experience multiple symptoms; this may help health-related quality of life improve among the growing population of
prostate cancer survivors.
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Introduction
Among men, prostate cancer is the second most common
cancer, after lung cancer, with an estimated 1.28 million new
cases diagnosed worldwide in 2018 [1]. Over the past decade,
prostate cancer incidence rates have risen substantially, espe-
cially in Northern and Western Europe [2]. Survival rates for
prostate cancer are high (and rising) so that more men are
living with this cancer than any other form of cancer [3, 4].
A range of treatment options are available for prostate can-
cer, including radical prostatectomy (RP), radiotherapy (exter-
nal beam (EBRT) or brachytherapy (BT)), observation (active
surveillance (AS) or watchful waiting (WW)) and chemother-
apy. However, none of these are clearly associated with lower
mortality, at least for localized disease [5]. In addition, all of
the treatments pose a high risk of adverse physical effects (e.g.
incontinence of urine, bowel problems and erectile dysfunc-
tion) as well as the more generalized cancer-related symptoms
(e.g. pain, insomnia, fatigue), all of which can persist long-
term [6, 7]. Moreover, survivors have poorer psychological
wellbeing than men in the general population [8].
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Cancer-related pain, fatigue and depression are recognized
to co-exist in a ‘symptom cluster’ among cancer patients and
survivors [9–11]. Moreover, there is some evidence that the
immune/inflammation pathway provides a biological basis for
the co-existence of these symptoms in a cluster [12].
However, a 2017 Expert Panel observed that symptom cluster
research remains extremely limited but that the increasing
focus on personalized care means that it is crucial that an
understanding of individual susceptibility to symptoms and
clusters of these is better understood [13].
The individual elements of the symptom cluster are
common among prostate cancer survivors. Up to three-
quarters of survivors may experience cancer-related fa-
tigue; urethral pain is reported by 16% following radiation
therapy; and on average, 18% of survivors have depres-
sion post-treatment [14–16]. Moreover, associations have
been reported between pairs of elements of the cluster
(e.g. depression and fatigue; pain and mental health) in
prostate cancer survivors [8, 17]. However, as far as we
are aware, no studies have investigated prevalence of the
pain-fatigue-depression symptom cluster in prostate can-
cer or which survivors are at greatest risk of experiencing
the cluster. Such information could be valuable in
informing targeting of supportive care interventions.
The aim of this analysis was to (i) investigate prevalence of
the pain-fatigue-depression symptom cluster among prostate
cancer survivors and (ii) identify factors associated with
experiencing the symptom cluster.
Methods
Subjects
The study setting was the island of Ireland, which comprises
the Republic of Ireland (RoI) and Northern Ireland (NI; part of
the UK). High-quality population-based cancer registries exist
in both NI and RoI. Study methods have been described in
detail elsewhere [18]. Briefly, all men diagnosed with invasive
prostate cancer (ICD10 C61) between 1st January 1995 and
31st March 2010 and who were still alive on 31st March 2011
were identified through the cancer registries. A stratified ran-
dom sample (n = 12,322, 54% of sampling frame) was select-
ed, to ensure approximately equal numbers < 5 and ≥ 5 years
post-diagnosis in both jurisdictions, and screened for eligibil-
ity by healthcare providers (HCPs), GPs in RoI and hospital
nurses in NI. To be eligible, men had to be (1) alive, (2) aware
of their prostate cancer diagnosis, (3) well enough to receive
and complete a questionnaire (in particular, have no cognitive
impairment), (4) able to understand English and (5) usually
reside in RoI or NI. Following screening, 6559 survivors were
considered eligible.
Data collection
Eligible survivors were invited to complete a postal question-
naire, a copy of which is available from the authors on request.
Non-responders were sent two reminders at two weekly inter-
vals. The questionnaire collected information on
sociodemographic characteristics; health at diagnosis, includ-
ing presence of urinary symptoms (increased frequency, pain
during urination, blood in urine), sexual symptoms (erectile
dysfunction/impotence) or comorbidities (lung or heart dis-
ease, stroke, depression, diabetes, high blood pressure, bowel
problems (constipation/diarrhoea), diverticular disease); mode
of diagnosis (asymptomatic/prostate-specific antigen (PSA)
detected, symptomatic/clinically detected, other); and treat-
ment(s) received (RP, EBRT, androgen deprivation therapy
(ADT), BT, chemotherapy, AS/WW). Men were asked to
identify whether they had ever or currently experienced any
of six physical after-effects following treatment (incontinence,
impotence, loss of sexual desire, bowel problems (diarrhoea/
constipation), gynecomastia, hot flashes/flushes or sweats).
These after-effect questions, the ones present on symptoms
at diagnosis, and mode of detection were developed by the
authors [19, 20]. Cancer-related pain and fatigue were
assessed using the European Organization for Research and
Treatment of Cancer Quality-of-Life Questionnaire Version
3.0 (EORTC QLQ-C30) [21]. The global health score ques-
tions on this instrument provided a measure of health-related
quality of life (HRQoL). Depression was assessed using the
21-question version of the Depression, Anxiety and Stress
Scale (DASS-21) [22]. The questionnaire was pretested for
face validity, acceptability and ease of completion among
men with prostate cancer prior to being used. Information on
clinical stage and Gleason grade at diagnosis and time since
diagnosis was abstracted from cancer registry records.
The study was approved by the Ethics Committee of the
Irish College of General Practitioners in the RoI and the NI
Office for Research Ethics. Participants provided written in-
formed consent.
Statistical analysis
Of the 6559 survivors sent questionnaires, 297 were subse-
quently discovered to have died [18]; 3348 returned a com-
pleted questionnaire and were included in the analysis dataset.
The three outcomes of interest – fatigue, pain and depression –
were scored as recommended [23, 24]. For fatigue and pain,
we used pro-rating to impute missing responses for subjects
who answered at least half, but not all, questions in the rele-
vant subscale; in these instances, missing responses were
filled with the mean value for that subject’s responses to the
questions they did answer; a fatigue score was imputed for
138 respondents (4.1%) and a pain score for 126 respondents
(3.8%). The range of possible scores for fatigue and pain was
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0–100 and for depression was 0–42. Initially the three vari-
ables were summarized, and Pearson correlations were com-
puted for each pair of variables. Then, three binary variables
were created classifying men according to whether or not they
scored in the range for clinically significant cancer-related
pain, clinically significant cancer-related fatigue and depres-
sion. The cut-offs used to define ‘caseness’ were ≥ 25 on the
pain scale; ≥ 39 on the fatigue scale; and ≥ 10 on the depres-
sion scale [22, 24]. An outcome symptom cluster variable was
constructed based on the presence of pain, fatigue and depres-
sion, with categories none, any one, any two and all of three
symptoms. Chi-square tests were used to compare survivor
characteristics by symptom cluster categories.
A multivariable logistic regression model of factors asso-
ciated with presence of the symptom cluster was developed
using a forward-stepwise selection approach (using a signifi-
cant level < 0.05 for inclusion). In this analysis, the symptom
cluster variable was collapsed into two categories: < 3 symp-
toms (none/any one/any two symptoms) vs all three symp-
toms. The candidate variables for inclusion in all models were
sociodemographic characteristics (age at diagnosis and sur-
vey, country of residence, marital status, whether lived alone
at diagnosis, highest level of education completed, working
status, first-degree family history of prostate cancer); diagno-
sis characteristics (urinary or sexual symptoms at diagnosis,
mode of diagnosis, comorbidities, time since diagnosis,
Gleason score at diagnosis, clinical stage at diagnosis); treat-
ment(s) received; current physical after-effects; and overall
HRQoL (classified as ≥ or < median score) (Table 1). Since
complete case analyses are usually biased, for the covariates,
if more than 3% of men had missing data, ‘missing’ was
included as a category. Goodness of fit of the final models
was checked using the Hosmer and Lemeshow test. A two-
sided p value of < 0.05 was considered to be statistically sig-
nificant throughout. Analyses were performed using STATA
V.15.0.
Results
Of the 3348 men who responded to the questionnaire, slightly
more than a quarter were 70 years of age or older at diagnosis;
35% had completed only primary level education; and almost
a quarter had a first-degree family history of prostate cancer
(Table 1). Presence of symptoms pre-diagnosis ranged from
7% for blood in urine to 51% for frequent urination. Nearly
half of participants were 2–5 years since diagnosis. Almost
one quarter had advanced stage (stage 3/4) disease at diagno-
sis. The most common treatments received were EBRT (51%)
and RP (28%). The most common current treatment after-
effects were loss of sexual desire (47%) and impotence
(59%). The median HRQoL score was 75.0 (out of a possible
100).
Table 1 Characteristics of prostate cancer survivors
n %
Total 3348 100.0
Sociodemographic characteristics
Age at diagnosis (years)
< 60 799 23.9
60–59 1631 48.7
≥ 70 918 27.4
Country of residence
Republic of Ireland 2338 69.8
Northern Ireland 1010 30.2
Marital status
Married/ living with a partner 2753 82.2
Other 558 16.7
Not reported 37 1.1
Live alone at diagnosis
No 2874 85.8
Yes 424 12.7
Not reported 50 1.5
Highest level of education at diagnosis
Tertiary 899 26.9
Secondary 1122 33.5
Primary 1187 35.4
Not reported 140 4.2
Employment status at diagnosis
Employed/self-employed 1522 45.5
Retired 1587 47.4
Other 215 6.4
Not reported 24 0.7
First-degree family history of prostate cancer
No 2448 73.1
Yes 791 23.6
Not reported 109 3.3
Diagnosis related
Mode of diagnosis
PSA-detected/asymptomatic 1860 55.6
Clinically detected/symptomatic 1148 34.3
Not reported 340 10.2
Comorbid conditions at diagnosis
No 1476 44.1
Yes 1872 55.9
Urinating more frequently before diagnosis
No 1387 41.4
Yes 1714 51.2
Not reported 247 7.4
Pain while urinating before diagnosis
No 2359 70.5
Yes 256 7.6
Not reported 733 31.9
Blood in urine before diagnosis
No 2384 71.2
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Prevalence of pain, fatigue and depression
Overall, at the time of the survey, 660 men (19.7%) reported
clinically significant cancer-related fatigue, 802 (24.0%) had
clinically significant cancer-related pain, and 481 (14.4%) had
depression.
Mean scores for the three symptoms were fatigue 24.0
(sd = 24.29, lowest = 0, highest = 100); pain 15.4 (sd = 25.0,
lowest = 0, highest = 100); and depression 4.5 (sd = 7.71, low-
est = 0, highest = 42). Men’s scores for each pair of symptoms
were strongly, and statistically significantly, correlated (pain
and fatigue, rho = 0.650; depression and fatigue, rho = 0.564;
depression and pain, rho = 0.454; all p < 0.001).
A total of 2879 (86.0%) men completed the pain, fatigue
and depression scales and were therefore included in the
symptom cluster analysis. Figure 1 demonstrates combina-
tions of pain, fatigue and depression. A total of 1024
(35.6%) men experienced one or more of the symptoms in
the cluster. A total of 127 men (4.4%) were affected solely
by fatigue, 260 (9.0%) were affected by pain alone, and 150
(5.2%) were affected by only depression. A total of 278 men
(9.7%) experienced two symptoms: fatigue and pain, 161
(5.6%); fatigue and depression, 59 (2.1%); and pain and de-
pression, 58 (2.0%). Two hundred nine men (7.3%) had all
three symptoms. Of the men who reported at least one symp-
tom, almost half experienced two or more (two symptoms,
27.2%; all three symptoms, 20.4%).
Factors associated with the symptom cluster
Table 2 displays the study characteristics by the four symptom
cluster categories (no symptoms, one symptom, two
Table 1 (continued)
n %
Yes 219 6.5
Not reported 745 22.3
Impotence or erectile dysfunction before diagnosis
No 2094 62.5
Yes 631 18.9
Not reported 623 18.6
Loss of interest in sex before diagnosis
No 2179 65.1
Yes 493 14.7
Not reported 676 20.2
Back pain before diagnosis
No 2165 64.7
Yes 506 15.1
Not reported 677 20.2
Clinical stage at diagnosis
Stage 1 110 3.3
Stage 2 2025 60.5
Stage 3 617 18.4
Stage 4 139 4.2
Not reported/not staged 457 13.6
Gleason grade
2 to 6 217 6.5
7 or 8 2165 64.7
8 to 10 600 17.9
Not known/not graded 366 10.9
Time since diagnosis (years)
2–5 1614 48.2
5–10 1075 32.1
≥ 10 659 19.7
Post-treatment symptoms
Incontinence of urine post-treatment
No 2810 83.9
Yes 538 16.1
Impotence post-treatment
No 1388 41.5
Yes 1960 58.5
Loss of sexual desire post-treatment
No 1776 53.1
Yes 1572 46.9
Bowel problems post-treatment
No 2852 85.2
Yes 496 14.8
Swelling or tenderness around nipple or upper chest area post-treatment
No 2998 89.6
Yes 350 10.4
Sweats or hot flashes post-treatment
No 2766 82.6
Yes 582 17.4
Treatment receiveda
Table 1 (continued)
n %
Radical prostatectomy 934 27.9
EBRT 1718 51.3
Brachytherapy 124 3.7
Hormone therapy 309 9.2
Other 170 5.1
Not reported 93 2.8
HRQoLb
≥Median 1674 50.0
<Median 1510 45.1
Not reported 164 4.9
EBRT external beam radiation therapy; HRQoL health-related quality of
life
aMutually exclusive hierarchical variable, based on primary treatment(s)
received
b From EORTC QLQC30; possible range 0–100; higher score indicates
better quality of life; median score 75
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symptoms and all three symptoms). There were significant
differences in age at diagnosis, country of residence, marital
status, living alone at diagnosis, highest level of education,
employment status at diagnosis, mode of diagnosis, symptoms
pre-diagnosis and post-treatment, clinical stage, Gleason
grade, treatment received and HRQoL across the symptom
cluster categories (all p < 0.05). Men in Northern Ireland,
who lived alone, had only primary level education and, who
were retired, more frequently had the pain-fatigue-depression
symptom cluster. The symptom cluster was associated with
having clinically detected cancer and symptoms, comorbidi-
ties, higher stage and higher Gleason grade at prostate cancer
diagnosis. It was also associated with each of the six post-
treatment physical symptoms assessed (urinary incontinence,
impotence, loss of sexual desire, gynecomastia, sweats/hot
flashes).
Table 3 shows the variables that were significantly associ-
ated with presence of the symptom cluster (i.e. experiencing
all three symptoms) in the multivariable model. Risk of
experiencing the symptom cluster was nearly 3-fold higher
in men in NI than RoI and two-fold higher in those with
primary only compared to tertiary education (OR = 2.01,
95%CI 1.29–3.12). Two pre-diagnosis symptoms were
significantly associated with the symptom cluster: urinating
more frequently (OR = 1.53, 95% CI 1.05–2.23) and back
pain (OR = 2.22, 95%CI 1.51–3.27). Four post-treatment
physical symptoms were significantly related to the symptom
cluster: incontinence of urine (OR = 1.91, 1.33–2.76); bowel
problems (OR = 1.95, 95%CI 1.36–2.80); gynecomastia
(OR = 2.06, 95%CI 1.35–3.14); and sweats or hot flashes
(OR = 1.56, 95%CI 1.07–2.26). Lower HRQoL was very
strongly related to the symptom cluster (OR = 44.09, 95%CI
17.88–108.73).
Discussion
This study investigated the prevalence and factors associated
with the pain-fatigue-depression symptom cluster among
prostate cancer survivors. Several sociodemographic and
prostate cancer specific symptoms were notably associated
with this symptom cluster in univariate analyses. Once these
symptoms were included in the multivariable model, many of
the previously statistically significant sociodemographic and
clinical factors became non-significant. The variables that
remained in the model largely related to physical symptoms
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Fig. 1 Prevalence of fatigue, pain and depression and combinations of
these in prostate cancer survivors, expressed as (a) number (percentage)
of survivors who completed the fatigue, pain or depression scales (n =
2879) and (b) number (percentage) of survivors who experienced at least
one of the symptoms (n = 1024)
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Table 2 Characteristics by symptom cluster category
Symptom cluster categorya
None (N = 1855) Any one (n = 537) Any two (n = 278) All three (n = 209)
n (%) n (%) n (%) n (%) p valueb
Sociodemographic characteristics 0.016
Age at diagnosis (years)
< 60 458 (24.7) 133 (24.8) 73 (26.3) 57 (27.3)
60–69 962 (51.9) 249 (46.4) 120 (43.2) 94 (45.0)
≥ 70 435 (23.4) 155 (28.8) 85 (30.6) 58 (27.7)
Country of residence < 0.001
Republic of Ireland 1307 (70.5) 374 (69.7) 179 (64.4) 97 (46.4)
Northern Ireland 548 (29.5) 163 (30.3) 99 (35.6) 112 (53.6)
Marital status 0.015
Married/ living with a partner 1569 (84.6) 439 (81.8) 227 (81.7) 162 (77.5)
Other 270 (14.6) 96 (17.9) 50 (18.0) 46 (22.0)
Not reported 16 2 1 1
Live alone at diagnosis 0.029
No 1631 (87.9) 467 (87.0) 237 (85.2) 172 (82.3)
Yes 203 (10.9) 67 (12.5) 41 (14.8) 36 (17.2)
Not reported 21 3 0 1
Highest level of education at diagnosis < 0.001
Tertiary 579 (31.2) 143 (26.6) 70 (25.2) 38 (18.2)
Secondary 668 (36.0) 186 (34.6) 96 (34.5) 58 (27.8)
Primary 549 (29.6) 192 (35.8) 108 (38.9) 104 (49.8)
Not reported 59 16 4 9
Employment status at diagnosis < 0.001
Employed/self-employed 929 (50.1) 250 (46.6) 111 (39.9) 70 (33.5)
Retired 855 (46.1) 250 (46.6) 129 (46.4) 107 (51.2)
Other 66 (3.6) 34 (6.3) 37 (13.3) 31 (14.8)
Not reported 5 3 1 1
First-degree family history of prostate cancer 0.491
No 1371 (73.9) 386 (71.9) 213 (76.6) 156 (74.6)
Yes 441 (23.8) 138 (25.7) 61 (21.9) 43 (20.6)
Not reported 43 13 4 10
Diagnosis related
Mode of diagnosis < 0.001
PSA-detected/asymptomatic 1157 (62.4) 287 (53.5) 125 (45.0) 81 (38.8)
Clinically detected/symptomatic 529 (28.5) 195 (36.3) 124 (44.6) 109 (52.1)
Not reported 169 55 29 19
Comorbid conditions at diagnosis < 0.001
No 939 (50.6) 199 (37.1) 96 (34.5) 54 (25.8)
Yes 916 (49.4) 338 (62.9) 182 (65.5) 155 (74.2)
Urinating more frequently before diagnosis < 0.001
No 885 (47.7) 226 (42.1) 91 (32.7) 55 (26.3)
Yes 864 (46.6) 281 (52.3) 163 (58.6) 145 (69.4)
Not reported 106 30 24 9
Pain while urinating before diagnosis < 0.001
No 1400 (75.5) 382 (71.1) 186 (66.9) 141 (67.5)
Yes 100 (5.4) 44 (8.2) 30 (10.8) 32 (15.3)
Not reported 355 111 62 36
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Table 2 (continued)
Symptom cluster categorya
None (N = 1855) Any one (n = 537) Any two (n = 278) All three (n = 209)
n (%) n (%) n (%) n (%) p valueb
Blood in urine before diagnosis < 0.001
No 1401 (75.5) 389 (72.4) 198 (71.2) 145 (69.4)
Yes 95 (5.1) 32 (6.0) 19 (6.8) 29 (13.9)
Not reported 359 116 61 35
Impotence or erectile dysfunction before diagnosis < 0.001
No 1262 (68.0) 331 (61.6) 167 (60.1) 116 (55.5)
Yes 298 (16.1) 112 (20.9) 65 (23.4) 61 (29.2)
Not reported 295 94 46 32
Loss of interest in sex before diagnosis < 0.001
No 1323 (71.3) 343 (63.9) 171 (61.5) 124 (59.3)
Yes 201 (10.8) 88 (16.4) 54 (19.4) 49 (23.4)
Not reported 331 106 53 36
Back pain before diagnosis < 0.001
No 1347 (72.6) 335 (62.4) 166 (59.7) 104 (49.8)
Yes 164 (8.8) 105 (19.5) 70 (25.2) 74 (35.4)
Not reported 344 97 42 31
Clinical stage at diagnosis < 0.001
Stage 1 66 (3.6) 14 (2.6) 7 (2.5) 9 (4.3)
Stage 2 1176 (63.4) 318 (59.2) 147 (52.9) 92 (44.0)
Stage 3 336 (18.1) 108 (20.1) 55 (19.8) 56 (26.8)
Stage 4 55 (3.0) 23 (4.3) 20 (7.2) 19 (9.1)
Not reported/not staged 222 74 49 33
Gleason grade 0.047
2 to 6 116 (6.3) 32 (6.0) 19 (6.8) 10 (4.8)
7 or 8 1259 (67.9) 339 (63.1) 171 (61.5) 123 (58.9)
8 to 10 309 (16.7) 109 (20.3) 58 (20.9) 49 (23.4)
Not reported/not staged 171 57 30 27
Time since diagnosis (years) 0.586
2–5 927 (50.0) 250 (46.6) 132 (47.5) 104 (49.8)
5–10 595 (32.1) 178 (33.1) 89 (32.0) 60 (28.7)
≥ 10 333 (18.0) 109 (20.3) 57 (20.5) 45 (21.5)
Post-treatment symptoms
Incontinence of urine post-treatment < 0.001
No 1632 (88.0) 450 (83.8) 201 (72.3) 137 (65.6)
Yes 223 (12.0) 87 (16.2) 77 (27.7) 72 (34.4)
Impotence post-treatment < 0.001
No 764 (41.2) 196 (36.5) 89 (32.0) 62 (29.7)
Yes 1091 (58.8) 341 (63.5) 189 (68.0) 147 (70.3)
Loss of sexual desire post-treatment
No 1040 (56.1) 261 (48.6) 117 (42.1) 70 (33.5)
Yes 815 (43.9) 276 (51.4) 161 (57.9) 139 (66.5)
Bowel problems post-treatment < 0.001
No 1660 (89.5) 434 (80.8) 216 (77.7) 133 (63.6)
Yes 195 (10.5) 103 (19.2) 62 (22.3) 76 (36.4)
Swelling or tenderness around nipple or upper chest area post-treatment < 0.001
No 1697 (91.5) 469 (87.3) 240 (86.3) 157 (75.1)
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present pre-diagnosis (frequent urination and back pain) and
after treatment (incontinence, bowel problems, gynecomastia,
hot flashes). This suggests that cancer-related symptoms are
more important indicators of being likely to experience this
symptom cluster than sociodemographic and (majority of)
clinical factors. The study also demonstrates that the three
elements of the system cluster can occur alone, in pairs or all
together in prostate cancer survivors, confirming previous,
more general, observations [25].
Prevalence of the symptom cluster
There is emerging (albeit inconsistent) data which suggest that
inflammatory and neuroimmune markers, such as cytokines,
may explain the clustering of pain, fatigue and depression in
people with cancer [12]. As far as we are aware, this is the first
study of this specific symptom cluster in prostate cancer sur-
vivors, and 7.3% (approximately one in every 13 survivors)
experienced all three symptoms. Comparative prevalence es-
timates are available from relatively few studies, in part be-
cause authors have investigated and reported a variety of dif-
ferent combinations of symptoms as potential clusters [26]. A
further complication is that, even among studies that have
examined pain, fatigue and depression, different instruments
were used to assess these. A recent study of 606 gastrointes-
tinal cancer patients reported that 9.6% experienced the
fatigue-pain-depression symptom cluster [27]. Higher figures
have been reported in studies of patients with lung cancer
(19%), which is often advanced at diagnosis, patients with
advanced cancer (20%) and patients following a palliative
pathway (27%) [11, 28, 29]. In terms of possible explanations
for the lower observed prevalence of the symptom cluster in
the current study population, this may be because the majority
of survivors had localized disease at diagnosis and many had
survived 10 years or more. In addition, symptoms had to be
scored at a level considered clinically important to be counted.
There are many more men living with prostate cancer
worldwide than with any other cancer (3.7 million men within
5 years of diagnosis alone) [30]. This indicates that, despite
the lower prevalence of the symptom cluster in prostate cancer
than in (some) other cancer populations, very large numbers
of prostate cancer survivors worldwide may be experiencing
the combination of pain, fatigue and depression (with many
more living with one or two of these symptoms).
Factors associated with the symptom cluster
As noted above, studies in which the participants had ad-
vanced cancer have generally reported higher prevalence of
the symptom cluster than the current study. The observed as-
sociations between presence of physical symptoms pre-
diagnosis (frequent urination and back pain) and the symptom
Table 2 (continued)
Symptom cluster categorya
None (N = 1855) Any one (n = 537) Any two (n = 278) All three (n = 209)
n (%) n (%) n (%) n (%) p valueb
Yes 158 (8.5) 68 (12.7) 38 (13.7) 52 (24.9)
Sweats or hot flashes post-treatment < 0.001
No 1606 (86.6) 435 (81.0) 214 (77.0) 134 (64.1)
Yes 249 (13.4) 102 (19.0) 64 (23.0) 75 (35.9)
Treatment received < 0.001
Radical prostatectomy 565 (30.5) 144 (26.8) 79 (28.4) 51 (24.4)
EBRT 942 (50.8) 285 (53.1) 145 (52.2) 111 (53.1)
Brachytherapy 91 (4.9) 18 (3.4) 5 (1.8) 3 (1.4)
Hormone therapy 122 (6.6) 59 (11.0) 34 (12.2) 29 (13.9)
Other 94 (5.1) 24 (4.5) 10 (3.6) 10 (4.8)
Not reported 41 7 5 5
HRQoL < 0.001
≥Median 1313 (70.8) 184 (34.3) 39 (14.0) 5 (2.4)
<Median 528 (28.5) 343 (63.9) 235 (84.5) 201 (96.2)
Unknown 14 10 4 3
EBRT external beam radiation therapy; HRQoL health-related quality of life
a Symptom cluster included fatigue, pain and depression. Symptom cluster was categorized into none, any one of these three symptoms, any two of these
three symptoms and all of these three symptoms
bχ2 test
Support Care Cancer
cluster may be because these symptoms can indicate more
advanced disease at diagnosis [31, 32]; thus, physical symp-
toms here may simply be acting as a marker of more advanced
cancer. Similarly, presence of comorbid conditions has been
linked with higher stage at prostate cancer diagnosis [33].
The study population was diagnosed over a long period, and
there were changes in prostate cancer treatment over that time;
notably radiotherapy became much more widely used, and
brachytherapy was introduced [34].We have previously reported
variation in the prevalence of post-treatment symptoms among
prostate cancer survivors according to primary treatment(s) re-
ceived [19]. Over the time of the study, there were also differ-
ences between RoI and NI in the frequency with which different
treatments were used [35]. This may help to explain the observed
association between country of residence and presence of the
symptom cluster in multivariable analyses.
Gynecomastia and hot flashes – two of the four post-
treatment symptoms related to the symptom cluster – are
side-effects of androgen deprivation therapy. Studies have pre-
viously indicated that these are associated with stigma, shame,
loss of masculinity and psychological distress [36, 37]. As
regards urinary incontinence, men who experience this may
fear smelling or leakage of urine and find using incontinence
pads embarrassing [38]; this may lead to social isolation and
increased risk of depression [39]. Although bowel dysfunction
has been noted to be particularly aggravating for prostate can-
cer survivors [40], men’s experiences of this, and its impact,
have not been well investigated. It is possible that men expe-
rience discomfort due to diarrhoea or constipation and, as for
urinary incontinence, may worry about leakage and embar-
rassment from wearing bowel incontinence pads. As well as
the adverse psychological and physical effects, these physical
symptoms may cause sleep disturbance [41]; sleep disorders,
in turn, are linked with cancer-related fatigue [42]. Thus, the
constellation of consequences of these post-treatment symp-
toms may explain their association with the pain-fatigue-
depression symptom cluster.
Laird et al. [28] reported a strong association between the
symptom cluster and worse physical functioning. We have
extended these findings by showing a very strong association
between lower HRQoL and the symptom cluster, which was
evident after adjustment for post-treatment physical symp-
toms which, themselves, might be expected to impact on
physical functioning. This finding has important implications.
Implications
The current findings suggest that intervention to alleviate ele-
ments of the symptom cluster might improve survivors’
Table 3 Multivariable logistic regression analyses: associations
between sociodemographic and clinical variables and the pain-fatigue-
depression symptom cluster
Multivariable analysesa
OR (95% CI) p value
Sociodemographic characteristics
Country of residence
Republic of Ireland 1.00
Northern Ireland 2.87 (1.99–4.15) < 0.001
Highest level of education at diagnosis
Tertiary 1.00
Secondary 1.55 (0.96–2.51) 0.073
Primary 2.01 (1.29–3.12) 0.002
Not reported 2.96 (1.17–7.51) 0.022
First-degree family history of prostate cancer
No 1.00
Yes 0.80 (0.54–1.20) 0.287
Not reported 4.15 (1.62–10.66) 0.003
Diagnosis related
Comorbid conditions at diagnosis
No 1.00
Yes 1.51 (1.04–2.18) 0.029
Urinating more frequently before diagnosis
No 1.00
Yes 1.53 (1.05–2.23) 0.029
Not reported 1.16 (0.47–2.83) 0.752
Back pain before diagnosis
No 1.00
Yes 2.22 (1.51–3.27) < 0.001
Not reported 1.08 (0.62–1.87) 0.791
Post-treatment symptoms
Incontinence of urine post-treatment
No 1.00
Yes 1.91 (1.33–2.76) 0.001
Bowel problems post-treatment
No 1.00
Yes 1.95 (1.36–2.80) < 0.001
Swelling or tenderness around nipple or upper chest area post-treatment
No 1.00
Yes 2.06 (1.35–3.14) 0.001
Sweats or hot flashes post-treatment
No 1.00
Yes 1.56 (1.07–2.26) 0.021
HRQoL
≥Median 1.00
<Median 44.09 (17.88–108.73) < 0.001
Unknown 36.83 (7.89–171.90) < 0.001
OR odds ratio; CI confidence interval; EBRT external beam radiation
therapy; HRQoL health-related quality of life
a Symptom cluster was dichotomised into less than three symptoms
(none, any one or any two of these three symptoms) vs all three symptoms
Logistic model for symptom cluster, goodness-of-fit test p = 1.000
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HRQoL. Both pharmacological and non-pharmacological
treatments and/or interventions have been shown to be effec-
tive for the components of the cluster. Pain can be treated
using resistance exercise techniques and medications [43,
44]. Mood disorders, including depression, can be treated
using medication and a variety of psychotherapies, depending
on the cause [45]. Physical activity also improves depression
and HRQoL among survivors [46]. Cognitive-behavioural
therapies, pharmacological agents and, again, physical activity
(aerobic or resistance) can be effective for treating cancer-
related fatigue [47, 48]. Considering this, it is possible that
an intervention/treatment that is competent in addressing one
symptom of the cluster (e.g. physical activity) may also alle-
viate another symptom (or, indeed, improve HRQoL). This
provides, as noted previously by Fleishman [25], an opportu-
nity to be imaginative in planning of survivor care and treat-
ment strategies. However, data from the current study popu-
lation indicates that supportive interventions to alleviate
symptoms of prostate cancer treatment are currently not fre-
quently used [49]. Moreover, research among clinicians indi-
cates considerable uncertainty in how to manage concurrent
symptoms in cancer patients and survivors [50], suggesting
professional education initiatives may be needed.
Strengths and limitations
Significant strengths of this study include the use of
population-based sampling frames to identify survivors
and the large sample size. As with any survey, there
may be systematic differences between responders and
non-responders. The 3348 survey respondents were youn-
ger and more often from RoI than non-respondents [18].
Among respondents, the 2879 men who answered all
three sets of symptom questions were older, more often
from NI, and had higher educational levels, making it
unclear whether prevalence of the symptom cluster is like-
ly to have been under- or overestimated. Measurement of
the components of the symptom cluster is not straightfor-
ward. While we used validated questionnaires [21, 22]
and thresholds previously shown to be associated with
clinical importance [24], the EORTC QLQC30 includes
only three items on fatigue and two on pain; the use of
other instruments focussed specifically on cancer-related
fatigue or pain, such as the EORTC QLQ-FA12 [51], may
have provided richer information. We developed the ques-
tions on physical symptoms pre-diagnosis and post-
treatment symptoms ourselves, and while these were
pre-tested among prostate cancer survivors, information
is lacking on their validity and psychometric properties;
this is a limitation. The cross-sectional design means care
must be taken in interpretation, particularly with regard to
the direction of associations between the symptom cluster
and post-treatment symptoms and HRQoL. It is possible
that men with depression, fatigue and pain may assess
their urinary incontinence or gynecomastia (e.g.) as worse
than men who are not experiencing the symptom cluster.
We have been unable to identify any population-level data
on the prevalence of the combination of fatigue, pain and
depression so we cannot comment on whether this is more
frequent among prostate cancer survivors than the general
male population.
Finally, while our focus was on the specific combination of
pain, fatigue and depression among prostate cancer survivors,
clusters of different combinations of symptoms among survi-
vors of other cancers have been reported [see, e.g. 51–54].
Prostate cancer survivors are at risk of a wide range of symp-
toms as a result of their cancer and its treatment [6, 55] and,
while it was not our intention to explore which symptoms co-
occur among prostate cancer survivors, research to investigate
this would be valuable.
Conclusions
This study indicates that one in every 13 prostate cancer
survivors experiences the pain-fatigue-depression symp-
tom cluster at levels considered clinically important.
Physical after-effects of prostate cancer treatment are
noteworthy indicators of this cluster. More attention
should be paid to identification and the support of survi-
vors who experience multiple symptoms; this may help
improve HRQoL among the growing population of pros-
tate cancer survivors.
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